- Home
- DAWN
as 12-20-2024 4:00pm EST
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.3B | IPO Year: | 2021 |
| Target Price: | $36.17 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.94 - $18.07 | Next Earning Date: | 10-30-2024 |
| Revenue: | $101,953,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 36.10% |
Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blackman Samuel C. | DAWN | HEAD OF R&D | Nov 15 '24 | Sell | $13.21 | 2,206 | $29,141.70 | 1,064,015 | |
| Dubow Adam | DAWN | GENERAL COUNSEL | Nov 15 '24 | Sell | $13.21 | 3,165 | $41,810.28 | 32,162 | |
| Bender Jeremy | DAWN | CHIEF EXECUTIVE OFFICER | Nov 15 '24 | Sell | $13.21 | 10,554 | $139,420.45 | 108,377 | |
| York Charles N II | DAWN | COO, CFO AND SECRETARY | Nov 15 '24 | Sell | $13.21 | 2,602 | $34,372.94 | 240,133 | |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Nov 8 '24 | Sell | $16.14 | 28,255 | $456,222.99 | 1,064,015 | |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Nov 7 '24 | Sell | $16.03 | 11,245 | $180,286.59 | 1,064,015 | |
| Blackman Samuel C. | DAWN | HEAD OF R&D | Oct 31 '24 | Sell | $16.02 | 500 | $8,010.00 | 1,064,015 |
Latest Day One Biopharmaceuticals Inc. News
DAWN Breaking Stock News: Dive into DAWN Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CoinDesk
6 days ago
How Trump Can Help Crypto on Day One
CoinDesk
6 days ago
How Trump Can Help Crypto on Day One
TechCrunch
15 days ago
Instagram locks out developers of third-party consumer apps
Insider Monkey
25 days ago
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?
GlobeNewswire
a month ago
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
GlobeNewswire
a month ago
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
MT Newswires
a month ago
Day One Biopharmaceuticals Insider Sold Shares Worth $456,223, According to a Recent SEC Filing
Compare DAWN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DAWN Day One Biopharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.